Novel Combinations of Radiation and Immunotherapy

放射治疗和免疫治疗的新组合

• 批准号: 9779938
• 负责人: Jennifer Jones
• 金额: $ 12.16万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9779938
• 关键词: Biological; Cancer Biology; Cells; Cessation of life; Colorectal; Combination immunotherapy; Combined Modality Therapy; Development; Disease; Disseminated Malignant Neoplasm; Goals; Immune; Immunology; Immunotherapeutic agent; Immunotherapy; Malignant Neoplasms; Mediating; Metastatic Neoplasm to the Liver; Methods; Pancreas; Patients; Radiation; Radiation Oncologist; Radiation therapy; Radiosurgery; Research; Research Personnel; Training; Translating; Unresectable; austin; curative treatments; immunotherapy trials; irradiation; neoplasm immunotherapy; novel; post-doctoral training; programs; radiation effect; responders and non-responders; tumor; tumor microenvironment; vaccine trial

As a radiation oncologist with specialized training in radiosurgery and graduate and postdoctoral training in both cancer biology and general immunology, the ultimate goal of my research is to discover effective ways to combine immunotherapies (IT) with radiation therapy (RT), to promote systemic tumor control while achieving local tumor control. Toward this goal, I led the development of the NCI ROB extracranial Stereotactic Body Radiation Therapy (SBRT) program, and I am the primary ROB Associate Investigator working with Tim Greten and Austin Duffy (NCI/TGIB) on NCI's colorectal liver metastases (15-C-0021), and pancreas (15-C-0027) RT + IT studies. Ultimately, we plan to study EV subsets in responders and non-responders from immunotherapy trials (such as these RT + IT trials, NCI VB vaccine trials, and other tumor immunotherapy trials at NCI), to translate the EV subset signatures into biological information that could be used for personalized and adaptive treatments for our patients.

作为一名辐射肿瘤学家，在癌症生物学和一般免疫学方面接受了放射外科和研究生和博士后培训的专业培训，我的研究的最终目标是发现有效的方法将免疫疗法（IT）与放射治疗（RT）结合起来，以促进全身性肿瘤控制，同时实现局部肿瘤控制。为了实现这一目标，我领导了NCI ROB颅外立体辐射治疗（SBRT）计划，我是与Tim Greten和Austin Duffy（NCI/TGIB）在NCI的结直肠肝转移酶（15-C-0021）和pancreas（15-C-0027）上与Tim Greten和Austin Duffy（NCI/TGIB）合作（NCI/TGIB）（NCI/TGIB）（15-CI/TGIB）（15-CI/TGIB）（15-CI）（15-C-0027）。最终，我们计划研究来自免疫疗法试验的反应者和无反应者的EV子集（例如，这些RT + IT试验，NCI VB疫苗试验和NCI的其他肿瘤免疫疗法试验），将EV EV子集签名转化为可用于我们患者的个性化和适应性治疗的生物学信息。